Lucid Diagnostics Closes $15 Million Preferred Stock Private Placement

• Lucid Diagnostics closed a $15 million private placement of Series C Convertible Preferred Stock on October 21, 2026.
• Shares sold for $1,000 each, with a common-stock conversion price of $0.3519 per share.
• Investors included existing long-term shareholders holding a majority of its 12% senior secured convertible notes due 2029.
• Net proceeds will support near-term commercial operations, working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610221620PR_NEWS_USPR_____NY79419) on October 22, 2026, and is solely responsible for the information contained therein.